Pharmaron LLC Receives A CFDA GLP Certificate For Its Safety Assessment Facility

BEIJING--(BUSINESS WIRE)--Pharmaron announced today that the company has received a Certificate of GLP Compliance, covering genetic toxicology and reproductive toxicology (DART Segments I and II), from the Chinese Food and Drug Administration (CFDA) for its GLP safety assessment facility in Beijing. This is the second GLP compliance certificate granted to this facility by the CFDA since 2013. As such, Pharmaron can offer full IND-enabling safety assessment services to partners in support of their IND filings with the CFDA.